Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Expands By 20.2%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 701,900 shares, an increase of 20.2% from the January 31st total of 583,900 shares. Currently, 6.4% of the company’s shares are sold short. Based on an average trading volume of 382,300 shares, the short-interest ratio is currently 1.8 days.

MIRA Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRA traded up $0.01 during midday trading on Friday, reaching $1.02. The company’s stock had a trading volume of 105,482 shares, compared to its average volume of 274,844. The firm has a 50 day moving average price of $1.15 and a two-hundred day moving average price of $1.30. MIRA Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $5.01. The firm has a market capitalization of $16.81 million, a price-to-earnings ratio of -1.81 and a beta of 2.31.

Institutional Trading of MIRA Pharmaceuticals

Several large investors have recently modified their holdings of the stock. International Assets Investment Management LLC acquired a new position in shares of MIRA Pharmaceuticals during the fourth quarter valued at about $29,000. Virtu Financial LLC purchased a new stake in MIRA Pharmaceuticals in the 4th quarter valued at $72,000. Renaissance Technologies LLC purchased a new stake in shares of MIRA Pharmaceuticals in the fourth quarter valued at about $52,000. Northern Trust Corp lifted its position in shares of MIRA Pharmaceuticals by 50.9% during the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after buying an additional 10,238 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in MIRA Pharmaceuticals in the fourth quarter worth $112,000. Institutional investors and hedge funds own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.